Innate Pharma (IPHA) Cash from Investing Activities (2019 - 2023)

Innate Pharma has reported Cash from Investing Activities for 5 years, with the latest figure at -$267875.4 in Q2 2023.

• For the quarter ending Q2 2023, Cash from Investing Activities rose 36.45% year-over-year to -$267875.4; the trailing twelve-month figure through Jun 2023 stood at -$2.0 million (up 88.5% YoY), and the FY2025 full-year result was $8.5 million, down 13.69% from the prior year.
• Cash from Investing Activities for Q2 2023 stood at -$267875.4, up from -$421487.4 in the prior quarter.
• The five-year high for Cash from Investing Activities was -$267875.4 in Q2 2023, with the low at -$69.4 million in Q2 2019.
• Historically, Cash from Investing Activities has averaged -$21.2 million across 5 years, with a median of -$7.2 million in 2020.
• Annual changes were most pronounced in 2021 — Cash from Investing Activities surged 97.77% — and 2022, when it sank 41.7%.
• Innate Pharma's Cash from Investing Activities stood at -$68.8 million in 2019, then jumped by 76.82% to -$15.9 million in 2020, then jumped by 93.42% to -$1.0 million in 2021, then surged by 59.82% to -$421487.4 in 2022, then soared by 36.45% to -$267875.4 in 2023.
• The last three Cash from Investing Activities figures came in at -$267875.4 (Q2 2023), -$421487.4 (Q2 2022), and -$1.0 million (Q4 2021), per Business Quant data.